Evaluation
Diagnosis and Management of Familial Hypercholesterolemia in Children and Adults-NO CREDIT
DIETITIAN INSTRUCTIONS
To apply for 1.0 continuing professional education units (CPEUs), please complete and submit your answers to the following evaluation form.
What were your educational needs at the start of the activity?
Please indicate your response to the following questions:
No
Somewhat
Yes
Not Applicable
Were your educational needs met?
1
2
3
4
5
NA
After having participated, are you now able to:
Strongly Disagree
Not Sure
Strongly Agree
Describe the prevalence and associated risk of familial hypercholesterolemia (FH) in order to increase awareness and understanding of the disease
1
2
3
4
5
Describe the importance of universal screening during childhood and cascade lipid screening of family members of known FH patients
1
2
3
4
5
Review management strategies to improve the care of patients with FH and reduce their elevated risk
1
2
3
4
5
Evaluate the clinical effects, safety and efficacy data for current and new treatment options for FH patients
1
2
3
4
5
Appraise treatment recommendations and evidence for screening, diagnosing and treating FH in both pediatric and adult patients (including women of childbearing potential and during pregnancy)
1
2
3
4
5
If
"Not Met"
, please explain for each objective.
Please rate the effectivness of the speakers
Low/Poor
High/Excellent
Not Applicable
Anne C. Goldberg, MD
1
2
3
4
5
NA
Jennifer G. Robinson, MD, MPH
1
2
3
4
5
NA
Samuel S. Gidding, MD, PhD
1
2
3
4
5
NA
Peter P. Toth, MD
1
2
3
4
5
NA
Matthew K. Ito, PharmD
1
2
3
4
5
NA
Did the speakers encourage questions/discussion or other participation from the audience?
Yes
Somewhat
No
NA
If the answer is
no
, please explain:
Strongly Disagree
Not Sure
Strongly Agree
Was the content presented examined with sceintific rigor and evidence-based?
1
2
3
4
5
Was the scope, depth, and level of content appropriate?
1
2
3
4
5
Did the invitation and syllabus accurately convey the purpose and content?
1
2
3
4
5
Did the speaker provide a disclosure and disclose any off-label/investigational use of products discussed during their presentation?
1
2
3
4
5
Were the activities (e.g. speaker questions/discussion, case studies) that assessed learning appropriate?
1
2
3
4
5
Was the acitivity fair, balanced, and free of commercial bias?
1
2
3
4
5
If you answered 1, 2, or 3 in the above question, please describe the factors that contributed to the bias:
As a result of participating in this activity, what will you do differently to improve the care of your patients?
(Note: You will be reminded of this answer in a follow-up email survey)
What other topics would you like to see addressed in future NLA CME activities?
(choose all that apply)
Implementation of Treatment Guidelines
No
Somewhat
Yes
NA
Clinical Trial Updates
No
Somewhat
Yes
NA
Genetic disorders and testing
No
Somewhat
Yes
NA
Advanced lipid testing
No
Somewhat
Yes
NA
Emerging biomarkers of atherosclerosis
No
Somewhat
Yes
NA
Atherosclerosis Imaging
No
Somewhat
Yes
NA
Hypertriglyceridemia
No
Somewhat
Yes
NA
Metabolic syndrome, diabetes, insulin resistance
No
Somewhat
Yes
NA
Hypertension
No
Somewhat
Yes
NA
Obesity management and weight loss
No
Somewhat
Yes
NA
Acute Coranary Syndrome
No
Somewhat
Yes
NA
HDL-C therapies
No
Somewhat
Yes
NA
Aggresive LDL-C lowering through combination therapies
No
Somewhat
Yes
NA
Special Populations: Women, Pediatrics, Ethnic Groups, HIV
No
Somewhat
Yes
NA
Other:
Additional comments or suggestions for improvement?
Submit
